STOCK TITAN

Exelixis Inc - EXEL STOCK NEWS

Welcome to our dedicated page for Exelixis news (Ticker: EXEL), a resource for investors and traders seeking the latest updates and insights on Exelixis stock.

Exelixis Inc. (symbol: EXEL) is a leading biopharmaceutical company that specializes in the discovery, development, and commercialization of small molecule therapies aimed at improving cancer treatment. Founded in the early 1990s, Exelixis has dedicated the past decade to establishing a robust development platform to bring new, effective cancer therapies to patients in need.

Exelixis’s flagship product, Cometriq® (cabozantinib), received its initial regulatory approval in late 2012 and has since been a cornerstone in the company’s portfolio. Cometriq is prescribed for the treatment of metastatic medullary thyroid cancer, while its variant Cabometyx is used for treating kidney and liver cancers.

Another significant achievement is the development and commercialization of Cotellic in partnership with Roche, targeted at melanoma treatment. These therapies have not only enhanced Exelixis’s market presence but also brought substantial improvements in patient outcomes.

Exelixis remains steadfast in its commitment to clinical excellence and patient care, consistently exploring new avenues for innovative cancer treatments. The company continues to engage in rigorous research and development activities, underpinned by strategic partnerships and collaborations.

Financially, Exelixis has shown solid performance with steady revenue growth driven by its commercial products and a promising pipeline of new therapies under development. The company’s dedication to research, patient care, and financial prudence makes it a notable entity in the biopharmaceutical landscape.

For more information about Exelixis and potential job opportunities, please visit their official website at www.exelixis.com.

Rhea-AI Summary

Exelixis, Inc. (NASDAQ: EXEL) announced encouraging results for cabozantinib in combination with immunotherapies for advanced colorectal cancer. Cohort 16 of the COSMIC-021 trial showed an objective response rate (ORR) of 10% and a disease control rate (DCR) of 71% among 31 patients. Median overall survival (OS) was 14 months. The CAMILLA trial cohort 2 reported an ORR of 27.6% with a DCR of 86.2%. The findings highlight cabozantinib's potential role in treating chemotherapy-refractory colorectal cancer. The data will be presented at ASCO GI on January 22, 2022.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.73%
Tags
none
-
Rhea-AI Summary

Tenaya Therapeutics (NASDAQ:TNYA) has selected TN-401 as a candidate gene therapy for treating genetic Arrhythmogenic Right Ventricular Cardiomyopathy (gARVC) caused by PKP2 gene mutations, which affect over 70,000 patients in the U.S. Additionally, the company plans to submit IND applications for TN-201 and TN-301 in the latter half of 2022. Tenaya has appointed Jennifer Drimmer as General Counsel, bringing over 17 years of experience. The company aims to advance several therapeutic candidates towards clinical trials while enhancing its operational capabilities.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.51%
Tags
none
-
Rhea-AI Summary

Exelixis reported approximately $1.08 billion in preliminary U.S. net product revenues for 2021, driven mainly by the cabozantinib franchise. The company estimates its 2022 net product revenues between $1.325 billion and $1.425 billion. With ongoing phase 3 pivotal trials for cabozantinib and the initiation of pivotal trials for XL092, Exelixis aims to grow its oncology portfolio. The company plans to expand its development team and operations, including a new facility on the East Coast. Financial guidance for 2022 includes R&D expenses of $725 million to $775 million and SG&A expenses of $400 million to $450 million.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.51%
Tags
Rhea-AI Summary

Exelixis has amended its May 2019 agreement with Iconic Therapeutics, gaining full rights to the anti-tissue factor antibody used in XB002 and oncology-specific rights to additional antibodies. In exchange for a one-time payment of $55 million, Exelixis can use the antibody in various applications, including drug conjugates. The company aims to develop a promising franchise targeting cancer therapy, with plans to report initial data from the ongoing XB002 clinical trial later this year.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.44%
Tags
none
-
Rhea-AI Summary

Exelixis, Inc. announced the completion of patient enrollment for CONTACT-03, a pivotal Phase 3 trial assessing the efficacy and safety of cabozantinib combined with atezolizumab versus cabozantinib alone in renal cell carcinoma patients who had progressed post immune checkpoint inhibitor treatment. The trial enrolled 523 patients, randomized to two arms, with primary endpoints focused on progression-free survival and overall survival. Initial results are anticipated upon data maturation, offering insights into treatment sequencing for advanced kidney cancer.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.84%
Tags
-
Rhea-AI Summary

Exelixis (NASDAQ: EXEL) will present a corporate overview at the 40th Annual J.P. Morgan Healthcare Conference on January 10, 2022, at 5:15 PM ET. CEO Michael M. Morrissey, Ph.D., will lead the presentation. Interested parties can access the webcast through www.exelixis.com and should connect 15 minutes early for any necessary software downloads. A replay will be available for 14 days post-event. Exelixis is focused on developing oncology therapies and has four products on the market, including CABOMETYX and COTELLIC.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.84%
Tags
conferences
Rhea-AI Summary

Exelixis has appointed Dr. Vicki L. Goodman as Executive Vice President, Product Development & Medical Affairs, and Chief Medical Officer. Dr. Goodman brings over 20 years of oncology experience, previously serving at Merck, Bristol Myers Squibb, and GlaxoSmithKline. Her role will involve leading Exelixis' clinical and medical affairs, particularly focusing on the ongoing CABOMETYX trials and the development of new therapeutics. She will also spearhead the company's expansion efforts on the East Coast, enhancing collaboration and growth opportunities.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.24%
Tags
management
-
Rhea-AI Summary

Exelixis, Inc. (Nasdaq: EXEL) announced the election of Jackie Wright to its Board of Directors, effective December 16, 2021. With extensive experience in technology and digital transformation from her roles at Microsoft, BP, and General Electric, Wright aims to enhance Exelixis' growth in the oncology sector. Her leadership is expected to drive digital initiatives and support the company’s mission to improve cancer treatment outcomes.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.23%
Tags
management
-
Rhea-AI Summary

Exelixis, Inc. has initiated the dose-escalation stage of the STELLAR-002 trial, exploring XL092, a next-generation tyrosine kinase inhibitor, in combination with immuno-oncology therapies for advanced cancers. Collaborating with Bristol-Myers Squibb and Nektar Therapeutics, the trial aims to assess safety and efficacy among patients with advanced solid tumors. The study will focus on renal cell carcinoma, urothelial carcinoma, and metastatic castration-resistant prostate cancer, with primary endpoints including objective response rates and progression-free survival.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.06%
Tags
Rhea-AI Summary

Exelixis plans to submit a supplemental New Drug Application (sNDA) to the FDA in early 2022 after presenting the first analysis of the COSMIC-312 phase 3 trial. This trial assesses the efficacy of cabozantinib with atezolizumab compared to sorafenib in treating advanced hepatocellular carcinoma (HCC). At 15.8 months follow-up, cabozantinib plus atezolizumab showed a 37% reduction in disease progression risk (PFS) versus sorafenib, though overall survival (OS) results were not statistically significant (HR: 0.90). The trial continues as planned for final OS analysis, anticipated in early 2022.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags

FAQ

What is the current stock price of Exelixis (EXEL)?

The current stock price of Exelixis (EXEL) is $33.82 as of December 24, 2024.

What is the market cap of Exelixis (EXEL)?

The market cap of Exelixis (EXEL) is approximately 9.7B.

What is Exelixis Inc. known for?

Exelixis Inc. is known for developing and commercializing small molecule therapies aimed at improving cancer treatment.

What are the main products of Exelixis?

The main products of Exelixis are Cometriq® (cabozantinib) for thyroid cancer, Cabometyx for kidney and liver cancer, and Cotellic for melanoma.

When was Cometriq first approved?

Cometriq received its initial regulatory approval in late 2012.

Who are the key partners of Exelixis?

Exelixis has partnered with Roche to bring Cotellic to market.

What type of cancer is Cometriq used to treat?

Cometriq is used to treat metastatic medullary thyroid cancer.

What is Cabometyx used for?

Cabometyx is used for the treatment of kidney and liver cancers.

Where can I find job opportunities at Exelixis?

Job opportunities at Exelixis can be found on their official website at www.exelixis.com.

How has the financial performance of Exelixis been?

Exelixis has shown solid financial performance with steady revenue growth driven by its commercial products and pipeline.

What kind of research does Exelixis focus on?

Exelixis focuses on the research and development of innovative therapies for cancer treatment.

What is the ticker symbol for Exelixis Inc.?

The ticker symbol for Exelixis Inc. is EXEL.

Exelixis Inc

Nasdaq:EXEL

EXEL Rankings

EXEL Stock Data

9.66B
281.04M
1.59%
89.36%
2.77%
Biotechnology
Biological Products, (no Disgnostic Substances)
Link
United States of America
ALAMEDA